Babil Caddesi, Tokelau

Emine Gunhan

This inventor holds 1 USPTO granted patent. Top assignee: University of California. Active years: 2006.


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Emine Gunhan: Innovator in Immunoselective Targeting Agents

Introduction

Emine Gunhan is a prominent inventor known for her groundbreaking work in the field of immunoselective targeting agents. Based in Babil Caddesi, Turkey, she has made significant contributions to neuroscience through her innovative inventions. Her research focuses on developing methods that enhance the selective targeting of neuronal cells, which has important implications for medical treatments.

Latest Patents

Emine Gunhan holds 1 patent for her invention titled "Immunoselective targeting agents and methods of use thereof." This patent provides immunoselective targeting agents that bind to transporters transiently accessible on the surface of neuronal cells. The invention outlines methods for selectively killing or promoting the survival of neuronal cells, showcasing her commitment to advancing medical science.

Career Highlights

Emine Gunhan is affiliated with the University of California, where she continues her research and development in the field of neuroscience. Her work has garnered attention for its potential to revolutionize treatments for neurological disorders.

Collaborations

Throughout her career, Emine has collaborated with notable colleagues, including Prabhakara V Choudary and Leo M Chalupa. These partnerships have enriched her research and expanded the impact of her inventions.

Conclusion

Emine Gunhan's contributions to the field of immunoselective targeting agents highlight her innovative spirit and dedication to improving medical treatments. Her work not only advances scientific knowledge but also holds promise for future therapeutic applications.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…